扶正化瘀方对不同病理阶段四氯化碳大鼠肝纤维化及活化星状细胞的影响

Therapeutic effects of Fuzheng Huayu decoction in different pathological stages CCl4-induced liver cirrhosis rat model and on hepatic stellate cells activation

目的:评价扶正化瘀方对不同病理阶段四氯化碳(CCl4)大鼠肝纤维化及活化星状细胞的影响。方法:用CCl4复合法制备大鼠肝纤维化模型,干预组分别于造模之日、2周末、4周末起以扶正化瘀方稀释液灌胃,在第2、4、6周末分批处死大鼠,观察各组大鼠肝组织病理学,采用计算机图像分析测定大鼠肝组织纤维化面积比例;测定α-平滑肌肌动蛋白(α-SMA)的积分光密度(IOD)值。组间数据比较用完全随机设计的单因素方差分析。结果:随着造模时间的延长,与正常组比较,2、4、6周末模型组、各干预组肝组织纤维化面积比例明显升高,α-SMA表达亦均有升高(P<0.05);与模型组比较,各干预组大鼠肝组织纤维化面积比例均减少,大鼠肝组织α-SMA的表达均有下调,且均为药物干预一组下降显著(P<0.05)。结论:扶正化瘀方在不同病理阶段均减少了α-SMA的表达,具有抗肝纤维化的作用,且越早进行干预治疗效果越好。

Objective To evaluate the influence of Fuzheng Huayu decoction on different pathological stages fibrotic liver tissue and activated hepatic stellate cells （HSCs）. Methods Use a carbon tetrachloride （CCl4）- induced liver cirrhosis rat model system. The drug intervention was administered via oral-gastric irrigation in building, the end of week 2 and 4. Rats were batch sacrificed at the end of week 2, 4, and 6. Liver fibrosis was evaluated by histology, and expression of a-smooth muscle actin （α-SMA） was determined by immunohistochemistry. Between-group comparisons were made by completely random design and ANOVA with Bonferroni correction. Results At the end of weeks 2, 4 and 6, the model group and drug intervention groups had significantly higher area ratio of liver fibrosis and higher expression of α-SMA than the normal group, but the three drug intervention groups had significantly less area ratio of liver fibrosis and less expression of α-SMA than the model group and the drug intervention 1 group showed the most robust decrease （P 〈 0.05）. Conclusion The Fuzheng Huayu decoction leads to down-regulated α-SMA expression and reduced degree of liver fibrosis on different pathological stages of fibrotic liver tissue, and the earlier drug intervention, the better the results.